Table 1.
Patient characteristics at baseline.
| (n = 38) | |
|---|---|
| Epidemiological characteristics | |
| Sex | |
| Male (%, male/all) | 95% (36/38) |
| Age (years) | 42.0 (8.8) |
| Transmission (%, n/all) | |
| MSM | 92% (35/38) |
| PWID | 8% (3/38) |
| HCV reinfection (%, n/all) | 21% (8/38) |
| Weight (kg) | 73.9 ± 11.3 |
| BMI (kg m–2) | 23.4 ± 2.74 |
| Laboratory parameters | |
| Hemoglobin (g dL–1) | 15.1 (1.50) |
| Platelet count (G L–1) | 234 ± 66.3 |
| White blood cell count (G L–1) | 5.88 ± 1.97 |
| Prothrombin time (%) | 86.0 (23.5) |
| Albumin (g dL–1) | 44.9 (5.30) |
| Creatinine (mg dL–1) | 0.97 (0.26) |
| Bilirubin (mg dL–1) | 0.55 (0.35) |
| AST (U L–1) | 83.5 (131) |
| ALT (U L–1) | 169 (385) |
| GGT (U L–1) | 102 (271) |
| FIB-4 | 1.33 (0.75) |
| HIV infection parameters | |
| CD4+ T-lymphocyte count (cells µL–1) | 650 ± 271 |
| HIV-RNA <50 copies mL–1 | 84% (32/38) |
| HIV-RNA <400 copies mL–1 | 89% (34/38) |
| HCV infection parameters | |
| AHC infection to treatment initiation (days) | 118 (88.0) |
| HCV-RNA (log IU mL–1) | 5.41 (1.52) |
| HCV-GT (%, n/all) | |
| 1a | 66% (25/38) |
| 1b | 11% (4/38) |
| 2 | 3% (1/38) |
| 3 | 13% (5/38) |
| 4 | 8% (3/38) |
| Liver stiffness (%, n/all) | |
| F0/F1 (<7.1 kPa) | 47% (18/38) |
| F2 (≥7.1 kPa and <9.5 kPa) | 24% (9/38) |
| F3 (≥9.5 kPa and <12.5 kPa) | 18% (7/38) |
| F4 (≥12.5 kPa) | 11% (4/38) |
Continuous variables are reported as mean ± standard deviation or median (interquartile range).
AHC: acute hepatitis C; ALT: alanine transaminase; AST: aspartate transaminase; BL: baseline; BMI: body mass index; DAA: direct-acting antiviral agent; GGT: gamma-glutamyl transpeptidase; GT: genotype; HCV: hepatitis C virus; MSM: men who have sex with men; SVR12: sustained virologic response at week 12 after end of treatment; TE: transient elastography.